As of 2026-11-05, the EV/EBITDA ratio of Crinetics Pharmaceuticals Inc (CRNX) is -16.42. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CRNX's latest enterprise value is 8,957.70 mil USD. CRNX's TTM EBITDA according to its financial statements is -545.58 mil USD. Dividing these 2 quantities gives us the above CRNX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 16.3x - 18.5x | 18.0x |
| Forward P/E multiples | 17.9x - 19.8x | 18.4x |
| Fair Price | (91.52) - (94.61) | (92.93) |
| Upside | -207.7% - -211.4% | -209.4% |
| Date | EV/EBITDA |
| 2026-08-31 | -16.42 |
| 2026-08-28 | -16.40 |
| 2026-08-27 | -16.40 |
| 2026-08-26 | -16.40 |
| 2026-08-25 | -16.40 |
| 2026-08-24 | -16.39 |
| 2026-08-21 | -16.37 |
| 2026-08-20 | -16.37 |
| 2026-08-19 | -16.37 |
| 2026-08-18 | -16.37 |
| 2026-08-17 | -16.38 |
| 2026-08-14 | -16.37 |
| 2026-08-13 | -16.32 |
| 2026-08-12 | -16.32 |
| 2026-08-11 | -16.30 |
| 2026-08-10 | -16.26 |
| 2026-08-07 | -16.25 |